Juan Andres - 28 Dec 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
28 Dec 2022
Transactions value $
-$318,140
Form type
4
Filing time
30 Dec 2022, 15:31:18 UTC
Previous filing
23 Dec 2022
Next filing
15 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $41.9K +2K +15.62% $20.93* 14.8K 28 Dec 2022 Direct F1
transaction MRNA Common Stock Sale -$360K -2K -13.51% $180.00 12.8K 28 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2K -0.98% $0.00 203K 28 Dec 2022 Common Stock 2K $20.93 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Juan Andres is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer